Yakimenko D. O.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

The clinical picture of Sjogren’s syndrome is various and includes manifestations of lesions of the exocrine glands, signs of nonspecific activation of the immune system (weakness, subfebrile condition, myalgia, arthralgia, arthritis of the joints of the hands and knees), organ-specific autoimmune pathology (autoimmune thyroiditis, hepatitis, sclerosing cholangitis, autoimmune hemolytic anemia). The peculiarities of the lesion of the joints in the SS allow us to establish their exact nature, sometimes only during long-term observation. The aim of the work was to study the state of the joints and bone mineral density in patients with SS and the possibility of correcting these disorders by including amaranth oil in therapy. An experimental study was conducted on 33 white Wistar rats of outbred breeding and clinical observation of 21 patients with Sjogren syndrome. On the model of dexamethasone joint damage in rats, the important pathogenetic role of glucocorticoids in the development of dystrophic-degenerative processes in cartilage and bone tissues was confirmed. The use of amaranth oil in these conditions led to significant positive changes, which was expressed in the inhibition of destructive changes in the bones and cartilage of experimental animals. The defeat of the osteo-articular system in patients with Sjogren’s syndrome was characterized by the presence of arthralgia and morning stiffness. Densitometry revealed a decrease in bone mineral density of the lumbar spine and femoral neck in patients who took glucocorticoids and in patients who did not take glucocorticoids, which can be explained by the negative effect of the inflammatory process on bone structure. The inclusion of amaranth oil in the complex treatment of patients with Sjogren’s syndrome ensured the preservation of bone mineral density due to the inhibition of negative changes in the metabolism of bone and cartilage tissue in patients with lesion of the musculoskeletal system. It can be assumed that this effect is associated with squalene – a natural antioxidant that contained in amaranth oil.

amaranth oil, Sjogren syndrome, dystrophic bone changes.

1. Vasilev VI. Klinika, diagnostika i differentsialnaya diagnostika bolezni Shegrena. Russkiy meditsinskiy zhurnal. Revmatologiya. 2008;16:638-49. [in Russiаn].
2. Orellana MF, Lagraviere MO, Boychuk DG, Major PW, Flores-Mir C. Prelevance of xerostomia in population-based samples: a systematic rewiev. J. Public. Health. Dent. 2006;66(2):152-8.
3. Rosseir V, Bart PA, Spertini F. Sjogren’s syndrome: a new approach to treatment. Rev. Med. Sci. 2012;18;8(337):843-7.
4. Both T, Dalm VA, van Hagen PM, van Deele PLA. Reviewing primary Sjogren’s syndrome: beyond the dryness. From pathophysiology to diagnosis and treatment. Int. J. Med. Sci. 2017;14(3):191-200.
5. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch. Intern. Med. 2004;164:1275-84.
6. Jiunn-Hong Kang, Herng-Ching Lin. Comorbidites in patient with primary Sjogren’s syndrom a registry-based case-control study. J. Rheumatol. 2010;37(16):1188-94.
7. Csepregi A, Szodaray P, Zeher M. Do antibodies predict autoimmune liver disease in primary Sjogren’s syndrome? Data of 180 patients upon a 5years follow up. Scand. J. Immunol. 2002;56:623-9.
8. Shornikova NS, Vasilev VI, Smirnov AV. Porazhenie sustavov pri bolezni Shegrena. Nauchno-prakticheskaya revmatologiya. 2002;1:13-6. [in Russiаn].
9.  Shornikova NS, Vasilev VI, Smirnov AV. Mineralnaya plotnost kostnoy tkani pri bolezni Shegrena. Nauchno-prakticheskaya revmatologiya. 2002;3:8-12. [in Russiаn].
10. Vasilev VI, Simonova MV, Safonova TN, Logvinenko OA. Sovremennyie podhodyi k ispolzovaniyu glyukokortikoidnyih i tsitotoksicheskih preparatov pri bolezni Shegrena. Sovremennaya revmatologiya. 2008;2:39-56. [in Russiаn].
11.  Shiboski SC, Shiboski CH, Criswell L, Bar AN, Shallacombe S, Lanfranchi H, et al. American college of rheumatology classification criteria for Sjogren’s syndrome a data-driven, expert consensus approach in the SICCA cohort. Arthritis Care res. 2012;64(4):475-87.

«Bulletin of problems biology and medicine» Issue 2 Part 1 (150), 2019 year, 216-220 pages, index UDK 616.7 – 008.6 – 08:615.322

10.29254/2077-4214-2019-2-1-150-216-220